onc206
Small moleculeexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2020 (NCT04541082)
Timeline
Indications
Studied for
- Astrocytoma · Phase 1
- Brain Neoplasms · Phase 1
- Central Nervous System Neoplasms · Phase 1
- Choroid Plexus Neoplasms · Phase 1
- Ependymoma · Phase 1
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Gliosarcoma · Phase 1
- Medulloblastoma · Phase 1
- Meningioma · Phase 1
- Neoplasms · Phase 1
- Neoplasms, Neuroepithelial · Phase 1
- Neuroectodermal Tumors · Phase 1
- Neuroectodermal Tumors, Primitive · Phase 1
- Oligodendroglioma · Phase 1
- Pinealoma · Phase 1
- Rhabdoid Tumor · Phase 1
Mechanism of action
clpP agonist
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07282587 | Phase 2 | Dec 15, 2025 | Jazz Pharmaceuticals |
| NCT04732065 | Phase 1 | Aug 23, 2021 | Chimerix, Mithil Prasad Foundation, Storm the Heavens Fund, The ChadTough Defeat DIPG Foundation, University of California, San Francisco |
| NCT04541082 | Phase 1 | Oct 26, 2020 | National Institutes of Health (NIH), Oncoceutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chimerix | For profit | 1 | 0 | 1 | 2021 |
| Jazz Pharmaceuticals | For profit | 1 | 1 | 1 | 2025 |
| Mithil Prasad Foundation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2020 |
| Oncoceutics, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Storm the Heavens Fund | Academic/Hospital | 1 | 0 | 1 | 2021 |
| The ChadTough Defeat DIPG Foundation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2021 |
8 organizations
Page 1 / 1